Navigation Links
Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
Date:4/16/2008

QUEBEC CITY, April 16 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc. (Victhom, TSX: VHB) today disclosed initial results from the ongoing human clinical trial of its Closed-Loop neuromodulation System (CLS) used in the Neurostep(TM) for the treatment of patients suffering from foot drop secondary to a central nervous system lesion. According to the Company, the initial results of the trial have demonstrated that the Neurostep(TM) is capable of collecting sensory signals from a nerve and of stimulating the appropriate muscle groups, which represents, to the knowledge of the Company, the world's first proof of concept in a human clinical trial of a CLS product used on peripheral nerves.

The ongoing human clinical trial on the Neurostep(TM) has two major objectives. The first objective is to evaluate the sensing and stimulation mechanisms of the product. The initial results suggest that the Neurostep(TM) is capable of collecting sensory signals from a nerve located in the thigh. The interim results also demonstrate the capacity of the Neurostep(TM), based on the information collected from the nerve, to stimulate the appropriate muscle group to lift the foot in the desired direction and in synchronization with the patient's gait.

The Company expects to announce later this year results on the second major objective of the trial aimed at evaluating the efficacy of the Neurostep (TM) in providing clinically measurable benefits, such as helping patients to walk faster and over longer distances.

Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division, said: "We are excited about the initial results coming out of the clinical trial, which further increase our confidence in the ability of the closed-loop technology to open the door to next generation products in the neuromodulation industry that can deliver therapy to patients in a more effective manner than the continuous or pre-programmed stimulation regimen delivered by current generation devices". Mr. Kameli also stated: "With these promising initial results on the CLS platform proof of concept in humans, Victhom is well positioned to leverage its unique technology for the development of new exciting indications".

The Neurostep(TM), a fully implantable investigational neuromodulation product designed to treat gait disorders (e.g., foot drop), is the first CLS product aimed at using the patient's own nervous system as the source for detection of intention to move and control their leg. Contrary to other systems that use surrogates such as external sensors, the Neurostep(TM) detects intrinsic muscle activities and surface sensation events from the nerve signals delivered to the spine and brain. This information is then used as the trigger for intervention through neurostimulation, as needed, to complete function.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
2. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
3. Angiotech announces director resignation
4. BioHorizons Announces the Purchase of Implant Logic Systems
5. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
6. Arpida Announces Conference Call on 17 April
7. Arpida Announces Agenda Items for Shareholders Meeting
8. BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
10. Boston Scientific Announces Japanese Approval of Heart Failure Lead
11. Vasogen Announces Implementation of Strategic Restructuring Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical ... (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for the ... granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media ... The new Media Cybernetics corporate branding reflects a results-driven revitalization for a company ... analysis. The re-branding components include a crisp, refreshed logo and a new web ...
(Date:5/23/2016)... 23, 2016 Oxitec CEO Hadyn ... at 10:15 a.m. ET before the United States House Committee ... mosquitos can play in controlling the spread of the ... virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... a self-limiting gene. Trials in Brazil , ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients found in certain ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... of Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):